Nexus Pharmaceuticals has received US FDA approval for its patent-pending new drug application Emerphed, premixed ephedrine in a ready-to-use 50 mg/10 mL vial. With no need for compounding, diluting, or mixing, the product saves staff time while reducing the potential for preparation error and waste. Each vial contains 50 mg ephedrine sulfate in 0.9% sodium chloride. The ephedrine sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Nexus Pharmaceuticals